Search research articles
Contact Us
Filters
Showing results (101-110 of 111) with videos related to
Page
of 12
Sort By:
JCO Precision Oncology
|
May 29, 2020
<i>CDK12</i>-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors
Emmanuel S Antonarakis, Pedro Isaacsson Velho, Wei Fu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 26, 2019
Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum
Lucia Nappi, Marisa Thi, Amy Lum, et al.
The Oncologist
|
November 20, 2020
Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer
Laura A Sena, Julia Fountain, Pedro Isaacsson Velho, et al.
Cancer
|
February 11, 2026
Evolving strategies in prostate cancer: Emerging approaches and unmet needs from the Bridging the Gaps in Prostate Cancer expert panel
Rana R McKay, Benjamin L Maughan, Alicia K Morgans, et al.
Frontiers in Oncology
|
October 3, 2022
Genomic landscape of advanced prostate cancer patients with <i>BRCA1</i> versus <i>BRCA2</i> mutations as detected by comprehensive genomic profiling of cell-free DNA
Umang Swami, Raquel Mae Zimmerman, Roberto H Nussenzveig, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 9, 2020
Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion <i>BRCA</i> Mutations among Patients with Advanced Solid Tumors
Neelima Vidula, Thereasa A Rich, Oliver Sartor, et al.
European Urology Oncology
|
March 24, 2024
Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide
Mamta Parikh, Catherine Tangen, Maha H A Hussain, et al.
Clinical Genitourinary Cancer
|
November 14, 2013
Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma
Neeraj Agarwal, Joaquim Bellmunt, Benjamin L Maughan, et al.
The New England Journal of Medicine
|
February 18, 2022
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer
Matthew R Smith, Maha Hussain, Fred Saad, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 9, 2025
NCCN Guidelines® Insights: Testicular Cancer, Version 2.2025
Timothy Gilligan, Daniel W Lin, Nabil Adra, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 111) with videos related to
Sort By:
Page
of 12
JCO Precision Oncology
|
May 29, 2020
<i>CDK12</i>-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors
Emmanuel S Antonarakis, Pedro Isaacsson Velho, Wei Fu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 26, 2019
Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum
Lucia Nappi, Marisa Thi, Amy Lum, et al.
The Oncologist
|
November 20, 2020
Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer
Laura A Sena, Julia Fountain, Pedro Isaacsson Velho, et al.
Cancer
|
February 11, 2026
Evolving strategies in prostate cancer: Emerging approaches and unmet needs from the Bridging the Gaps in Prostate Cancer expert panel
Rana R McKay, Benjamin L Maughan, Alicia K Morgans, et al.
Frontiers in Oncology
|
October 3, 2022
Genomic landscape of advanced prostate cancer patients with <i>BRCA1</i> versus <i>BRCA2</i> mutations as detected by comprehensive genomic profiling of cell-free DNA
Umang Swami, Raquel Mae Zimmerman, Roberto H Nussenzveig, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 9, 2020
Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion <i>BRCA</i> Mutations among Patients with Advanced Solid Tumors
Neelima Vidula, Thereasa A Rich, Oliver Sartor, et al.
European Urology Oncology
|
March 24, 2024
Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide
Mamta Parikh, Catherine Tangen, Maha H A Hussain, et al.
Clinical Genitourinary Cancer
|
November 14, 2013
Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma
Neeraj Agarwal, Joaquim Bellmunt, Benjamin L Maughan, et al.
The New England Journal of Medicine
|
February 18, 2022
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer
Matthew R Smith, Maha Hussain, Fred Saad, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 9, 2025
NCCN Guidelines® Insights: Testicular Cancer, Version 2.2025
Timothy Gilligan, Daniel W Lin, Nabil Adra, et al.
Page
of 12